CompletedPhase 1NCT04062981
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Studying Lennox-Gastaut syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SK Life Science, Inc.
- Principal Investigator
- Marc Kamin, MDSK Life Science, Inc.
- Intervention
- Carisbamate(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2019 – 2022
Study locations (5)
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Oregon Health and Science University, Portland, Oregon, United States
- The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center), Salt Lake City, Utah, United States
- UW Valley Medical Center, Renton, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04062981 on ClinicalTrials.govOther trials for Lennox-Gastaut syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06924086The Children's Adaptive Deep Brain Stimulation for Epilepsy TrialUniversity College, London
- RECRUITINGPHASE3NCT05066217An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeEpygenix
- RECRUITINGNCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALYJazz Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT06464653Pallidothalamic Tracts Electrical Stimulation for Lennox-Gastaut SyndromeLiankun_Ren
- RECRUITINGNCT05374824Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut SyndromeAnn & Robert H Lurie Children's Hospital of Chicago
- ACTIVE NOT RECRUITINGPHASE4NCT05044819Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral SolutionJazz Pharmaceuticals